RCM
AVEO

RA Capital Management’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

RA Capital Management’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-506,276
Closed -$11.4M – 30
2018
Q2 		$11.4M Hold
506,276
– – 0.74% 23
2018
Q1 		$14.7M Hold
506,276
– – 1.12% 18
2017
Q4 		$14.1M Sell
506,276
-626,589
-55% -$19.5M 1.18% 17
2017
Q3 		$41.4M Buy
1,132,865
+289,307
+34% +$8.95M 3.74% 10
2017
Q2 		$18.7M Buy
+843,558
New +$6.64M 2.15% 15

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DVC
Deer VI & Co Larchmont, New York $2.23M AUM 9.32% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

RA Capital Management's AVEO Position: Q3 2018 in Review

RA Capital Management sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q3 2018, closing a stake of 506,276 shares — an estimated $11.4M sold.

RA Capital Management first reported a position in AVEO in Q2 2017 and held it in 5 quarters. The position peaked at $41.4M in Q3 2017. 101 funds tracked by Wall St. Rank hold AVEO as of Q3 2018.

  • RA Capital Management reported no remaining AVEO Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • RA Capital Management sold 506,276 AVEO Pharmaceuticals, Inc. shares in Q3 2018, an estimated $11.4M.
  • RA Capital Management first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2017 and held it in 5 quarters.
  • RA Capital Management's AVEO Pharmaceuticals, Inc. position peaked at $41.4M in Q3 2017.
  • 101 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q3 2018.

Based on RA Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.